Sign in

    John Evans

    Chief Executive Officer at Beam Therapeutics Inc
    Board
    Since January 2017
    Age
    46 years
    Education
    Holds an MBA in Healthcare Management from Wharton, an M.S. in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.
    Tenure
    Joined Beam Therapeutics as Chief Executive Officer and board member in January 2017.

    Also at Beam Therapeutics Inc

    AS
    Amy Simon
    Chief Medical Officer
    CB
    Christine Bellon
    Chief Legal Officer and Secretary
    GC
    Giuseppe Ciaramella
    President

    About

    John Evans is a biotechnology executive with a strong track record in driving innovation and leadership within the industry. He has built a career through diverse roles in companies such as Agios Pharmaceuticals, ARCH Venture Partners, and other notable organizations, which provided him with deep expertise in corporate development and portfolio leadership.

    He joined Beam Therapeutics in January 2017 as the Chief Executive Officer and a member of the Board, where his strategic guidance has been pivotal in advancing precision genetic medicine.

    His academic background from prominent institutions further underpins his professional achievements, while his board memberships at multiple related ventures reflect his broad influence and commitment to the biotechnology sector.

    $BEAM Performance Under John Evans

    Past Roles

    OrganizationRoleDate RangeDetails
    ARCH Venture Partners Venture Partner April 2017 - March 2021 N/A
    Agios Pharmaceuticals, Inc. Senior Vice President for Corporate Development and Portfolio Leadership September 2009 - April 2017 Early employee and leadership team member
    Infinity Pharmaceuticals, Inc. Unknown N/A Worked there prior to Agios
    McKinsey & Company Pharmaceuticals Practice Member N/A Participated in the pharmaceuticals practice
    MedImmune Unknown N/A Worked at MedImmune

    External Roles

    OrganizationRoleDate RangeDetails
    Orbital Therapeutics, Inc. Board Member N/A Biotechnology company focused on mRNA therapeutics

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$685,000 AnnualIncreased from $650,000 in 2022
    Stock Awards$1,722,375 At grant dateRSUs granted computed per FASB ASC 718
    Option Awards$3,423,499 At grant dateStock options granted computed per FASB ASC 718
    All Other Compensation$17,675 AnnualIncludes sabbatical payments ($5,000), commuting benefits ($1,575), 401(k) matching ($9,900), cell phone allowance ($1,200)
    Qualifying Termination Payment$2,362,932 Upon qualifying terminationConsists of Cash Severance ($685,000), Bonus Payment ($411,000), Health Care Continuation ($29,266), Equity Acceleration ($1,237,666)
    Change in Control Payment$2,386,024 Upon change in controlIncludes Equity Acceleration of 100% of unvested awards
    Change in Control with Qualifying Termination Payment$9,190,154 Upon change in control with qualifying terminationConsists of Cash Severance ($1,027,500), Bonus Payment ($616,500), Health Care Continuation ($43,899), Equity Acceleration ($7,502,256)

    Performance Compensation

    Data from  FY 2023

    Non-Equity Incentive Plan Compensation

    MetricDetail
    Target Award$411,000 (60% of base salary)
    Actual Payment$431,550 (105% of target)
    Performance MetricsCorporate performance goals covering Clinical, Research & Development, Manufacturing, Organizational, and Financial objectives
    ThresholdsNo threshold specified
    Maximum (Cap)No maximum specified
    WeightsBonus awarded at 105% of the target based on strong corporate performance
    Vesting ScheduleNot applicable (cash bonus)
    Evaluation Period2023
    Plan DetailsDetermined under the 2019 Cash Incentive Plan; compensation committee and Board holistically assessed goal achievement